Table 1 Numbers of HCT in Europe 2019 by indication, donor type and stem cell source.

From: Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

  Transplant activity 2019
No. of patients
Allogeneic Autologous Total
Family Unrelated   Allo Auto Total
HLA-id Twin Haplo ≥ 2MM Other family   BM BM+  
BM PBPC Cord All BM PBPC BM PBPC Cord BM PBPC Cord Only PBPC Cord
Myeloid malignancies 294 2562 9 13 367 1359 14 73 0 417 5292 118 0 245 1 10,518 246 10,764
Acute myeloid leukemia 227 1799 5 12 268 986 9 56 0 253 3305 87 0 237 0 7007 237 7244
 1st Complete remission 144 1163 1 9 154 523 4 37 0 153 1852 38 0 193 0 4078 193 4271
 Not 1st complete remission 58 427 4 3 74 327 4 16 0 72 848 35 0 41 0 1868 41 1909
AML therapy-related or myelodysplasia-related changes 25 209 0 0 40 136 1 3 0 28 605 14 0 3 0 1061 3 1064
Chronic myeloid leukemia 7 103 1 1 6 46 0 0 0 20 209 2 0 0 0 395 0 395
 Chronic phase 3 54 1 0 2 13 0 0 0 7 91 2 0 0 0 173 0 173
 Not chronic phase 4 49 0 1 4 33 0 0 0 13 118 0 0 0 0 222 0 222
MDS or MD/MPN overlap 52 475 3 0 64 259 4 14 0 130 1283 26 0 7 1 2310 8 2318
MPN 8 185 0 0 29 68 1 3 0 14 495 3 0 1 0 806 1 807
Lymphoid malignancies 312 1321 8 6 207 841 9 51 1 346 2093 60 30 22,610 0 5255 22,640 27,895
Acute lymphatic leukemia 267 745 6 0 124 478 7 34 1 286 1044 52 0 66 0 3044 66 3110
 1st Complete remission 149 535 3 0 54 243 5 23 0 144 686 24 0 62 0 1866 62 1928
 Not 1st complete remission 118 210 3 0 70 235 2 11 1 142 358 28 0 4 0 1178 4 1182
Chronic lymphocytic leukemia 4 40 0 0 6 19 0 0 0 3 99 0 0 11 0 171 11 182
Plasma cell disorders—MM 2 89 0 3 5 24 0 1 0 5 140 0 7 13,245 0 269 13,252 13,521
Plasma cell disorders—other 0 5 0 0 5 3 0 0 0 0 14 0 0 442 0 27 442 469
Hodgkin lymphoma 11 113 0 1 32 112 1 3 0 12 147 2 10 2175 0 434 2185 2619
Non Hodgkin lymphoma 28 329 2 2 35 205 1 13 0 40 649 6 13 6671 0 1310 6684 7994
Solid tumors 3 2 0 0 3 14 0 0 0 2 4 1 18 1529 0 29 1547 1576
Neuroblastoma 2 2 0 0 3 9 0 0 0 0 1 0 10 489 0 17 499 516
Soft tissue sarcoma/Ewing 1 0 0 0 0 2 0 0 0 0 1 1 2 245 0 5 247 252
Germinal tumors 0 0 0 0 0 0 0 0 0 0 1 0 2 431 0 1 433 434
Other solid tumors 0 0 0 0 0 3 0 0 0 2 1 0 4 364 0 6 368 374
Nonmalignant disorders 731 343 25 7 123 205 65 55 1 530 461 58 7 561 1 2604 569 3173
Bone marrow failure—SAA 185 140 0 5 21 54 5 10 0 181 138 10 0 1 1 749 2 751
Bone marrow failure—other 56 28 2 1 20 18 8 9 0 75 52 4 0 0 0 273 0 273
Thalassemia 154 45 9 0 2 11 17 9 1 42 52 0 1 0 0 342 1 343
Sickle cell disease 163 87 8 0 26 9 12 1 0 11 7 0 0 0 0 324 0 324
Primary Immune deficiencies 136 28 6 0 44 103 21 19 0 174 169 19 4 8 0 719 12 731
Inh. disorders of Metabolism 32 12 0 1 10 9 2 5 0 46 33 25 2 13 0 175 15 190
Autoimmune disease—MS 0 0 0 0 0 0 0 0 0 0 1 0 0 442 0 1 442 443
Autoimmune disease—SSC 0 0 0 0 0 0 0 0 0 0 0 0 0 55 0 0 55 55
Autoimmune disease—-other 5 3 0 0 0 1 0 2 0 1 9 0 0 42 0 21 42 63
Others 21 14 0 0 11 17 5 6 0 36 42 5 0 16 0 157 16 173
Total patients 1361 4242 42 26 711 2436 93 185 2 1331 7892 242 55 24,961 2 18,563 25,018 43,581
Re/additional transplants 36 155 0 2 59 332 2 11 1 68 547 22 5 3691 0 1235 3696 4931
Total transplants 1397 4397 42 28 770 2768 95 196 3 1399 8439 264 60 28,652 2 19,798 28,714 48,512
  1. The bold numbers indicate the subtotals of the rows (i.e. the number of myeloid malignancies = the total of acute myeloid leukemia + chronic myeloid leukemia + MDS or MD/MPN overlap + MPN).